We combine research with treatment in a novel way, with the aim of enhancing quality of life. For example, if a patient has inflamed gums, they won’t only be examined by a dental consultant; they will also see rheumatoid arthritis, eye, heart, lung and kidney specialists. Our Chronic Disease Research Cohort, eventually involving 3,000 patients, should provide answers to important questions, such as whether cardiovascular disease makes someone’s rheumatoid arthritis worse, and if successfully treating rheumatoid arthritis has a beneficial effect on a patient’s cardiovascular disease.
Early diagnosis of disease is often crucial to successful treatment, but the Rheumatology Research Group led by Professor Chris Buckley are working to identify inflammatory rheumatoid arthritis before it progresses. They are developing a biomarker assay that can be used by GPs to test on patients with mild joint inflammation. By identifying those at high risk of developing the condition, treatment can start immediately to prevent it progressing.
Respiratory research interests are wide ranging from primary lung epithelial and macrophage function, the effects of aging and respiratory disease upon neutrophil function and phenotype, to animal models of inflammatory lung disease, vitamin D biology, as well as biomarker development.
We undertake clinical trials in the areas of idiopathic pulmonary fibrosis, pneumonia, asthma, COPD and alpha-one anti-trypsin deficiency. There is also interest in lung cancer biology and identifying novel targets for therapy.